RLAY Relay Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RLAY

Price (delayed)

$18.03

Market cap

$3.95B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.56

Enterprise value

$3.86B

?
Relative Growth: Rel. Growth: 42
Relative Strength: Rel. Strength: 97
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 34
Highlights
The equity is up by 39% since the previous quarter and by 34% year-on-year
The EPS has increased by 19% year-on-year
RLAY's gross profit is up by 24% year-on-year but it is down by 3.1% since the previous quarter
Relay Therapeutics's revenue has increased by 24% YoY but it has decreased by 3.1% from the previous quarter
RLAY's quick ratio is down by 17% since the previous quarter and by 11% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://relaytx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of RLAY

RLAY stock price

How has the Relay Therapeutics stock price performed over time
Intraday
-6.82%
1 week
-4.3%
1 month
-7.25%
1 year
305.17%
YTD
113.12%
QTD
-3.63%

Financial performance

How have Relay Therapeutics's revenue and profit performed over time
Revenue
$10.35M
Gross profit
$10.35M
Operating income
-$310.44M
Net income
-$286.04M
Gross margin
100%
Net margin
-2,763.6%
Relay Therapeutics's operating margin has increased by 27% YoY but it has decreased by 8% from the previous quarter
The net margin has grown by 26% YoY but it has contracted by 8% from the previous quarter
RLAY's gross profit is up by 24% year-on-year but it is down by 3.1% since the previous quarter
Relay Therapeutics's revenue has increased by 24% YoY but it has decreased by 3.1% from the previous quarter

Price vs fundamentals

How does RLAY's price correlate with its fundamentals

Growth

What is Relay Therapeutics's growth rate over time

Valuation

What is Relay Therapeutics stock price valuation
P/E
N/A
P/B
3.88
P/S
353.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
372.88
The EPS has increased by 19% year-on-year
The P/B is 90% higher than the 5-year quarterly average of 2.2 and 54% higher than the last 4 quarters average of 2.7
The equity is up by 39% since the previous quarter and by 34% year-on-year
The stock's price to sales (P/S) is 106% more than its last 4 quarters average of 184.1 but 27% less than its 5-year quarterly average of 517.7
Relay Therapeutics's revenue has increased by 24% YoY but it has decreased by 3.1% from the previous quarter

Efficiency

How efficient is Relay Therapeutics business performance
The return on sales has increased by 26% year-on-year but it has declined by 8% since the previous quarter
The return on invested capital has declined by 7% year-on-year but it has increased by 4.1% since the previous quarter
The company's return on equity rose by 3.6% QoQ
The ROA is up by 3.5% QoQ but it is down by 3.5% YoY

Dividends

What is RLAY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RLAY.

Financial health

How did Relay Therapeutics financials performed over time
RLAY's total assets is up by 38% QoQ and by 33% YoY
Relay Therapeutics's total liabilities has increased by 35% from the previous quarter and by 23% YoY
The debt is 97% less than the equity
Relay Therapeutics's debt to equity has decreased by 40% from the previous quarter and by 40% YoY
The equity is up by 39% since the previous quarter and by 34% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.